FDA clearance for ARIES® respiratory assay, welcoming Nanosphere
Earlier this month we were delighted to attend the American Association for Clinical Chemistry’s Annual Scientific Meeting & Clinical Lab Expo — better known as the AACC conference — in Philadelphia. Along with nearly 20,000 other clinical lab professionals, we wholeheartedly supported the meeting’s keen focus on the need to be beyond reproach when it comes to data accuracy and test reliability.
Late Breaking Sessions
The late-breaking sessions were particularly interesting. One focused on the Zika virus epidemic, including Emergency Use Authorizations from FDA (our own Zika Assay EUA was announced just a few days after AACC). Another compelling session looked at disruptive technologies for clinical testing, such as new methods for blood sampling or for transporting patient samples.
Luminex had its own noteworthy moments at the meeting. Our ARIES® Flu A/B & RSV Assay received FDA clearance, allowing us to announce that great news during the conference. The second assay cleared by the FDA for use on our ARIES® Systems, delivers results in less than two hours for three respiratory pathogens: influenza A virus, influenza B virus, and respiratory syncytial virus.
United with Nanosphere
AACC was the first conference where we got to share our booth with Nanosphere, the newest member of the Luminex family. Nanosphere focuses on molecular microbiology, offering diagnostic tools for rapid and accurate detection of respiratory, gastroenteric, and bloodstream infections. We’ve been excited about working together since the acquisition was first announced in May, and it was great to have our first united presence at this meeting — especially since our booth was always teeming with attendees! Thanks to the many people who took time out of a busy conference to learn about how the Luminex platforms can make a difference in clinical labs.
We hope you enjoyed Philly as much as we did! We’re already looking forward to next year’s AACC meeting in San Diego.
